MCCORMICK PAUL 4
4 · Cardiogenesis Corp /CA · Filed May 17, 2011
Insider Transaction Report
Form 4
Cardiogenesis Corp /CACGCP.PK
MCCORMICK PAUL
Director
Transactions
- Disposition to Issuer
Common Stock
2011-05-17−978,926→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2011-05-17$0.17/sh−7,500$1,253→ 0 totalExercise: $0.29Exp: 2018-05-19→ Common Stock (7,500 underlying) - Disposition to Issuer
Stock Option (right to buy)
2011-05-17$0.24/sh−50,000$11,850→ 0 totalExercise: $0.22Exp: 2019-05-20→ Common Stock (50,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2011-05-17$0.13/sh−22,500$2,858→ 0 totalExercise: $0.33Exp: 2017-04-18→ Common Stock (22,500 underlying) - Disposition to Issuer
Stock Option (right to buy)
2011-05-17$0.08/sh−100,000$7,700→ 0 totalExercise: $0.38Exp: 2020-05-17→ Common Stock (100,000 underlying)
Footnotes (2)
- [F1]Disposed of pursuant to that certain Amended and Restated Agreement and Plan of Merger, dated April 14, 2011, by and among CryoLife, Inc., CL Falcon, Inc., and Cardiogenesis Corporation in exchange for cash consideration equal to $0.457 per share on the effective date of the merger (the "Merger"). This transaction is exempt under Rule 16b-3(e).
- [F2]Option cancelled pursuant to the Merger in exchange for cash consideration equal to the difference between $0.457 and the exercise price of the Option multiplied by the number of Options canceled. This transaction is exempt under Rule 16b-3(e).